Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentT1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control
TAMBORLANE W, CHENG P, GAL R, KOLLMAN C, VAN NAME M, LYNCH J, NELSON B. T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-1340-p.Peer-Reviewed Original ResearchTarget HbA1c levelT2D youthHbA1c levelsMedtronic MiniMedResidual endogenous insulin secretionHigher mean HbA1c levelsBoehringer Ingelheim GmbHMean HbA1c levelEndogenous insulin secretionOverweight/obesePoor diabetes outcomesChi-square testMann-Whitney UBoehringer Ingelheim PharmaceuticalsT2D durationClinical characteristicsInsulin therapyGlycemic controlT1D patientsDiabetes careDiabetes outcomesRisk factorsC-peptideInsulin secretionLogistic regression